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Synopsis
Differentiated thyroid cancer is characterized by an excellent long-term prognosis
which unlike other head and neck carcinomas is not definitively influenced by regional
lymph node metastasis. The relative rarity of the disease coupled with its tendency for
delayed metastatis and its low mortality make a prospective randomized trial comparing
treatment outcomes difficult. As a result, the effect of cervical lymph node metastases on
survival is unclear making meaningful recommendations for management somewhat
subjective and arbitrary. The purpose of this review is to discuss guidelines for the
management of the neck in differentiated thyroid cancer while reviewing the available
literature.

Introduction
The American Cancer Society estimates that there will be 33,550 new cases of
thyroid cancer for 2007, representing approximately 2% of all cancers in the United
States.1 Differentiated thyroid carcinoma (DTC) includes papillary thyroid carcinoma
(PTC) and follicular thyroid carcinoma (FTC), which are both derived from thyroid
follicular cells. DTC comprises approximately 90% of all thyroid cancers, and carries an
excellent long-term prognosis.2 In fact, two large database studies involving 15,698 and
53,856 cases of thyroid carcinoma treated in the United States demonstrated a 10-year
survival rate for PTC of 98% and 93%, respectively, and a 10-year survival rate for FTC
of 92% and 85%, respectively.3, 4 Unlike squamous cell carcinoma of the head and neck,
where regional metastases have a definite negative prognostic impact, the effect of
cervical nodal involvement on survival in DTC has not been clearly demonstrated. The

2

high survival rate combined with the unclear impact of regional metastases has resulted in
inconsistent approaches to the management of the neck in thyroid cancer over the years.
Indeed, the relative rarity of the disease, combined with its favorable prognosis, limits the
ability to compare different treatment protocols by prospective randomized clinical trials.3
If long-term survival is the standard metric of all treatment options, then the goal of
limiting morbidity and recurrence becomes even more important. Therefore, the
management of the neck in DTC must take these factors into account.
In 2006, the American Thyroid Association (ATA) Guidelines Taskforce released
updated recommendations for the management of DTC, including guidelines for the
management of the neck.5 The purpose of this review is to expand upon those guidelines
while discussing the evidence leading to those recommendations and highlighting special
considerations and newer techniques proposed for the management of the neck in thyroid
carcinoma. The focus of this review will be on DTC, which comprises the vast majority of
thyroid cancers.

Background
Pattern of nodal metastasis
Lymph node metastases occur frequently in PTC. A review of 1,038 previously
untreated patients with DTC who presented to Memorial Sloan Kettering over a 55-year
period showed the incidence of nodal metastasis in PTC to be 56%.6 Several more recent
studies have confirmed the incidence of nodal metastasis in PTC to be in the range of 6065%.7-10 Ito et al11 investigated the rate of nodal metastasis from papillary thyroid
microcarcinoma (PTMC), defined as tumor size < 10mm, and still found an incidence

3

close to 50%. Qubain et al12 investigated the lymph nodes of 80 patients with DTC that
were deemed pathologically N0 by standard hematoxylin and eosin staining. Of the 71
patients with PTC, 54% had lymph node micrometastases when examined
immunohistochemically with cytokeratins (AE1/AE3). Lymph node metastases in FTC
occur less frequently. In their 55-year review, Shaha et al reported 21% with cervical
metastases at presentation.6
Several studies have attempted to define the pattern of lymph node metastases for
PTC, as has been demonstrated for squamous cell carcinoma of the head and neck.10, 13-16
Goropoulos et al10 studied 39 patients in whom a central neck dissection (CND) was
performed. Some of these patients also had a lateral neck dissection (LND) and all
patients had post-operative I-131 scans. They discovered that metastasis to the central
compartment was common (64%), as was metastasis to the ipsilateral cervicolateral
compartment (51.2%.) Contralateral cervicolateral metastasis occurred in 33.3% of the
patients and never occurred without associated metastases to the central compartment and
the ipsilateral side. None of the patients studied had disease in the lateral compartments
while lacking metastasis to the central compartment, leading the authors to suggest that
the nodal status of the central compartment is a valuable indicator of lymphatic
involvement of the lateral compartments.
Gimm et al13 also demonstrated that the cervicocentral compartment was the most
frequent site of metastasis, but differentiated between ipsilateral and contralateral central
compartments. Of the 35 patients studied, 24 had metastasis to the ipsilateral
cervicocentral compartment, while only 5 had metastases to the contralateral
cervicocentral compartment. All five of these patients had T3 or T4 tumors. Nineteen
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patients had metastases to the ipsilateral cervicolateral compartment while no patients had
metastases to the contralateral cervicolateral compartment and only 1 patient had a
mediastinal metastasis. Contrary to the suggestion of Goropoulos et al10 advocating the
central compartment as an indicator of lateral involvement, Gimm at el13 discovered
ipsilateral cervicolateral metastases in the absence of central metastases in 5 patients.
At a Japanese institution where neck dissections are performed routinely for all
sized PTC, a review of 259 cases of PTMC confirmed the preference of metastases to
spread to the central (64%) and ipsilateral nodes (44.5%.)8 They did not clarify whether
the status of the central compartment was predictive of the lateral compartment, but they
did further divided the central compartment to report the incidence of pretracheal (43.2%),
ipsilateral (36.3%), and contralateral (18.9%) positive nodes. Other groups have further
characterized the pattern of lymph node metastases from PTC to the lateral nodes.
Kupferman et al14 reported the distribution of positive nodes from 44 therapeutic neck
dissections, and found levels II (52%), III (57%), and IV (41%) to be most frequently
involved. However, the incidence of level V nodes (21%) was high enough for the authors
to advocate a comprehensive (level II through V) neck dissection when lateral metastases
are present. Sivanandan and Soo16 analyzed specimens from 80 therapeutic neck
dissections and had similar results and conclusions.
The rate and number of nodal metastases in PTC have been shown to be associated
with the size of the thyroid tumor.9, 15, 17 Ito et al9 studied 759 cases of PTC and showed
that the frequency of metastasis to the central compartment was 38.3% for tumors
measuring 1 cm or smaller, and rose significantly to 79.0% for tumors larger than 4 cm.
Like Gimm13 , they found some patients (11.2%) to be positive for lateral but negative for
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central node metastasis, questioning the reliability of the central compartment as an
indicator for lateral involvement.

Effect of nodal metastases on survival
As demonstrated above, it is clear that lymph node metastasis in PTC is frequent
and has a predictable pattern. However, it remains controversial whether the presence of
lymph node metastases, either overt or occult, has an impact on prognosis. It is this fact
that has prevented adoption of a universal approach to management of the neck in thyroid
cancer.
Traditionally, it has been suggested that the presence of regional metastases has no
effect on survival.18-24 Hughes et al19 performed a matched-pair analysis of patients with
differentiated thyroid cancer and N0 versus NI neck involvement. There were 100 patients
in each group, and they were matched according to age, tumor size, histology, and
intrathyroidal extent. All lacked distant metastases. There was no significant difference in
survival. Shaha et al18 and McConahey et al20 each presented retrospective series of over
800 patients and also found that the presence of lymph node metastases had no effect on
survival. Scheuman et al25 found that N1 status in PTC did influence survival for patients
with T1-T3 status, but not for those with T4 status. A more recent nested case-controlled
study suggests that lymph node metastasis does have an adverse effect on prognosis.26
Mazzaferri et al21 found that cervical metastases carried a higher cancer mortality rate in
patients with FTC, but not in patients with PTC.
Increasing age, male gender, distant metastases, extrathyroidal spread, and large
tumor size, have all been shown to be more consistently linked to a worse prognosis3, 4, 18,
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20, 21

In fact, when univariate analysis is applied to the presence of regional lymph nodes,

some have found it to be a favorable prognostic indicator.19 Although this appears to be
counterintuitive, the finding can be explained by the positive influence of younger age.
PTC in younger patients is often associated with nodal metastases. In this instance, age
appears to influence survival more than metastatic disease, and therefore biases the results.
A study comparing patients of the same age with and without metastatic disease would
more properly address this question. Such a study in older patients has demonstrated an
adverse impact of nodal disease on survival.27

Effect of nodal metastases on recurrence
Up to 30% of patients with DTC develop recurrent metastatic cervical disease with
minimal adverse impact on survival.21, 23, 28 Patients with nodal disease at presentation
have a higher incidence of recurrent disease in the cervical region. Ito et al9 evaluated
626 patients with papillary carcinoma whose primary tumor was larger than 1 cm using
multivariate analysis. They found that patients with central node metastasis had an
independently significant decreased disease-free survival when compared to those without
metastasis. The size and number of the metastatic nodes were also demonstrated to impact
recurrence. In McConahey’s20 study of 859 patients over a 24-year treatment period, the
presence of metastatic nodes at the time of initial examination was associated with a 10fold increase in the risk of developing a nodal recurrence. Scheumann et al25
demonstrated that N1 patients had a significant increase in recurrence when compared to
N0 patients with T1-T3 tumors. In Hughes et al’s19 matched-pair analysis the recurrence
rate was higher in N1 patients (17%) than in N0 patients (11%), but did not reach
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significance. However, when their analysis was limited to patients over the age of 45, the
recurrence in N1 patients was 31% and was significantly greater than in the N0 patients
(8%).
The effect of metastases, whether occult or overt, on prognosis and recurrence has
important implications for the management of the neck. This is further discussed below in
the context of indications for neck dissection.

Preoperative
Fine-Needle Aspiration
Fine needle aspiration (FNA) is considered the procedure of choice in the
evaluation of thyroid nodules according to the ATA Guidelines Taskforce.5 The
procedure is minimally invasive, accurate, and cost effective. FNA also plays an
important role in the workup of a neck mass. Cervical adenopathy can be the presenting
finding in patients with DTC, especially young people with PTC.29 FNA is advocated in
the pre-operative workup of a neck mass to aid in appropriate diagnosis and pre-operative
planning. It potentially differentiates metastatic PTC from metastatic squamous cell
carcinoma, thus allowing an appropriately directed search and treatment of the respective
primary tumor and neck disease. In younger patients, lymphoma is often suspected and an
excisional biopsy of the cervical node may be performed. Cervical metastases are
common in younger patients with PTC, however, and FNA could allow for differentiation
from lymphoma prior to excisional biopsy, thus preventing a potentially inappropriate
procedure. Finally, measurement of thyroglobulin in a 1 ml saline wash-out of the needle
used for the biopsy has been shown to be an easy, inexpensive, and reliable method of
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increasing the diagnostic yield of FNA.30, 31 This is especially true of cystic lymph nodes,
which frequently result in nondiagnostic cytology.32

Ultrasound, MRI, CT
Preoperative staging of the neck aids in surgical decision-making for DTC.
Physical examination alone can underestimate the involvement of regional lymph nodes,
which is quite frequent in PTC. Ultrasonography is non-invasive, well-tolerated, and
improves the identification of cervical adenopathy. Kouvaraki et al28 at the University of
Texas M.D. Anderson Cancer Center retrospectively reviewed 212 patients with thyroid
carcinoma who underwent preoperative ultrasonography. They reported that
ultrasonography detected lymph node or soft tissue metastases in neck compartments
believed to be uninvolved by physical exam in 39% of the patients. Thus, ultrasonography
altered the surgical procedure in these patients, potentially minimizing recurrence in the
neck.
Although the specificity of ultrasonography for cervical lymph node metastases is
very high, its sensitivity has been shown to be as low as 36.7% for lateral compartments
and as low as 10.9% for the central compartments.33-35 Interestingly, Ito et al33 examined
the usefulness of preoperative ultrasonographic examination of the neck in patients with
PTMC and determined that only the lateral compartment nodes that were identified on
ultrasound preoperatively had clinical relevance, mitigating the concern for low sensitivity
of the technique. They reviewed 590 patients, 67 of which had evidence of metastases on
preoperative ultrasound. These 67 all underwent a modified radical neck dissection
(MRND) as part of their management. Of the 523 patients without preoperatively
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detectable metastasis, 249 underwent MRND and 274 did not. Despite the fact that more
than 40% of the patients who underwent MRND had pathologic evidence of metastasis,
the MRND and observations group did not statistically differ in lymph node recurrence
rates (< 1.5% for both) when followed for a mean of over 4 years.
It should be noted that the sonographic criteria for identifying lymph nodes
suspicious for metastases is not limited to lymph node size. Architectural features of the
lymph node itself that indicate malignancy have been well described.28, 36 Benign lymph
nodes are typically oval and flattened with a smooth cortex and a central fatty hilum.
Features that can indicate malignancy include a rounded bulging shape, replaced fatty
hilum, eccentric cortical widening, irregular margins, decreased or heterogeneous
echogenicity, alteration in intranodal vascularity, cystic areas, and calcifications. These
findings can be present even in small nodes and are not appreciated on simple palpation.
One limitation of ultrasonograpy is that it is operator dependant. However, it is
less expensive than computed tomography and magnetic resonance imaging. Additionally,
the 2006 ATA Guidelines recommend ultrasound of the thyroid for the workup of all
patients with one or more suspicious thyroid nodules.5 Preoperative neck ultrasound to
evaluate the contralateral thyroid lobe as well as cervical lymph nodes is also
recommended for all patients undergoing thyroidectomy for malignant cytologic findings
on biopsy. An experienced sonographer, with appropriate communication from the
referring specialist, can potentially extend a diagnostic thyroid ultrasound to include
surveillance of the lateral compartments when suspicion for malignancy is heightened by
patient history, by sonographic features of the thyroid nodule, or by preliminary cytologic
findings of the thyroid nodule if ultrasound guided FNA is being performed. This would
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minimize the time required and number of interventions needed during the preoperative
workup. Although the ATA guidelines suggest that CT and MRI may be useful in some
clinical settings (large, rapidly growing, and invasive tumors), they do not recommend the
routine preoperative use of these studies.5 If computed tomography is utilized, it is
important to remember that iodinated contrast dye can interfere with radioactive iodine
uptake, and thus should be avoided when performing a neck CT with suspicion of thyroid
cancer.

FDG-PET
Positron emission tomography (PET) has gained popularity in the diagnostic
workup and post-treatment surveillance of squamous cell carcinoma of the head and neck.
Its role in thyroid carcinoma has not been clearly delineated and the ATA guidelines do
not recommend its use pre-operatively. Early studies suggest, however, that PET or
PET/CT scanning may be useful in patients with an indeterminate fine-needle aspiration
of thyroid nodules.37, 38 In this setting, the test has a high negative predictive value, and
has been proposed to be a way to reduce the number of hemithyroidectomies for what is
ultimately proven to be a benign nodule. Another potential role for PET/CT in thyroid
carcinoma is when recurrence is suspected (either clinically or due to elevated
thyroglobulin) and radioiodine whole-body scintigraphy (WBS) is negative.39-41 This
situation is difficult from both a diagnostic and therapeutic standpoint. Since the tumor is
not radioiodine avid it cannot be treated by radioiodine ablation. It also cannot be
accurately localized by whole body scintigraphy to allow for surgical excision. In this
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scenario, the use of PET/CT has been shown to have a high positive predictive value and
led to a change in management in greater than 40% of patients in 3 different studies.39-41
As PET imaging gains greater use in other diseases, the prevalence of PET
incidentalomas of the thyroid will increase. In a review of 4,136 patients who underwent
PET imaging for known non-thyroid malignancies, 45 demonstrated focal uptake with the
thyroid gland.42 In 50% of the 32 patients for whom a cytologic diagnosis was available,
the tumor was malignant. Given this high prevalence of malignancy, all PET
incidentalomas of the thyroid must be evaluated for thyroid carcinoma.
2006 ATA Guidelines: Preoperative neck ultrasound for the contralateral lobe and cervical
(central and bilateral) lymph nodes is recommended for all patients undergoing
thyroidectomy for malignant cytologic findings on biopsy. Routine preoperative use of
other imaging studies (CT, MRI, PET) is not recommended.

Operative
Central Compartment
Metastases from PTC occur frequently in the central compartment. The central
compartment is generally defined as the space bounded by the common carotid arteries
laterally, the hyoid bone superiorly, and the innominate vessels inferiorly. The
recommendation for or against the routine dissection of the central compartment is based
upon the risk of lymph node recurrence versus the morbidity of the procedure.
Some authors have suggested that due to the high frequency of central
compartment metastases, that elective dissection of the central compartment should be
performed in all patients with PTC.12, 13, 43 Others have attempted to actually prove that
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careful dissection of the central compartment at the time of thyroidectomy can positively
influence patient survival.44 Ito et al9 reviewed 759 patients and demonstrated that the
frequency of central node metastasis increased in relation to tumor size. They also
showed that central node metastasis was an independent prognostic factor of disease-free
survival in patients with PTC larger than 1 cm. An argument against the routine
performance of a CND in papillary thyroid carcinoma is that it has been shown to be
associated with increased morbidity. Both Henry et al45 and Cheah et al46 showed that
CND was associated with a statistically significant increased risk of both transient and
permanent hypocalcemia. Roh et al7 were able to demonstrate that serum parathyroid
hormone levels significantly decreased immediately after neck dissection in patients with
PTC and remained low for several weeks when transient. In this study, the risk of
hypocalcemia was further increased when LND was performed in addition to CND. None
of these studies showed a statistically increased rate of recurrent laryngeal nerve injury
with CND. Another argument for routine CND is that reoperation for recurrence is
associated with significantly higher morbidity than an initial operation, and anything that
can be done to minimize the risk of recurrence and reoperation should be employed.43
A 2007 evidence based review of the literature performed by White et al47 at the
University of Michigan attempted to settle the debate on routine central compartment
lymph node dissection. Their goal was to answer these 3 important questions: 1) Does
central node dissection decrease recurrence or disease-specific mortality in PTC? 2) Does
central node dissection increase the risk of hypothyroidism and recurrent laryngeal nerve
injury? 3) Does reoperation in the central neck compartment for recurrent PTC increase
the risk of hypoparathyroidism and recurrent laryngeal nerve injury?
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No prospective randomized data exist to answers these questions. After review of
13 studies, which include one prospective study and multiple retrospective cohort studies
and case series, White et al47 concluded that based on the currently available evidence that
CND “may” decrease recurrence and “likely” improves disease-specific survival. They
also found that although CND may be associated with an increased risk of
hypoparathyroidism and unintentional nerve injury at initial operation, the increased risk
of these complications associated with reoperation for recurrence in the central neck
compartment supports the more aggressive initial opertation. They concluded that
evidence-based recommendations support CND for PTC in the hands of experienced
surgeons.
The 2006 ATA guidelines5 are in accordance with the University of Michigan
literature review. They recommend that routine central-compartment neck dissection
should be considered for patients with PTC and suspected Hurthle cell carcinoma. Due to
the low rate of metastases in FTC, they suggest that near-total or total thyroidectomy
without CND may be appropriate for that diagnosis. Finally, they offer thyroidectomy
without CND and followed by radioactive iodine (RAI) therapy as alternative approach
for papillary and Hurthle cell cancers.
2006 ATA Guidelines: Routine central-compartment (level VI) neck dissection should be
considered for patients with papillary thyroid carcinoma and suspected Hurthle carcinoma.
Near-total or total thyroidectomy without central node dissection may be appropriate for
follicular cancer, and when followed by radioactive iodine therapy, may provide an
alternative approach for papillary and Hurthle cell cancers.
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Lateral compartments
In PTC, lymph node metastases are also common in the lateral neck, specifically
the ipsilateral side. Since these metastases are frequently occult, discussion of the
management of the lateral neck must be framed in the context of clinically negative and
clinically positive.
The approach to the clinically negative neck has traditionally differed in Japan as
compared to the United States. Studies from Japan indicate that patients were more likely
to undergo a lateral neck dissection as part of the elective management for DTC.8, 22, 33, 48
A contributing factor to this is that postoperative RAI therapy is rarely employed in Japan.
Because of this, Japanese centers have provided insight into the effect of an elective neck
dissection for DTC in the absence of RAI, specifically for PTMC (tumor size < 1 cm).
Wada et al8 compared 235 patients who underwent prophylactic neck dissection for
PTMC to 155 patients who underwent thyroidectomy for presumably benign disease and
were discovered to have PTMC post-operatively. These 155 patients, therefore, did not
undergo a neck dissection as part of there management and served as controls. Both
groups were similar in regards to age, gender, and length of follow-up (greater than 53
months mean for both). They discovered that the recurrence rate did not differ between
the prophylactic group and the “observation” group (0.43% vs. 0.65%) and that it was low
for both groups. They concluded that prophylactic neck dissection is not beneficial in
patients with PTMC. Ito et al33 investigated 523 patients with PTMC who did not have
detectable lateral node metastasis on ultrasonography. Of these patients, 249 underwent
prophylactic LND and 274 did not. After a mean follow-up of over 4 years, there was no
statistical difference in regards to lymph node recurrence-free survival. They also
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concluded that LND is not necessary in patients with PTMC without lymph node
metastases detected on ultrasonography preoperatively.
Indeed, PTMC has a benign course. It is frequently found incidentally at autopsy
and its discovery is a situation where completion thyroidectomy may be unnecessary
according to the ATA guidelines.5, 49 The prevalence of ultrasound-guided FNA biopsy
has led to an increase in its diagnosis, thus forcing further consideration of its clinical
significance. In another study, Ito et al34 offered a trial of observation for patients with
PTMC. Of 732 patients, 162 opted for observation. During follow up, more than 70% of
the primary tumors either did not change or decreased in size, and lateral compartment
metastasis appeared in only 1.2% of patients. This is despite the fact that metastases were
histologically confirmed in 50% of the patients in the surgically treated group. This again
questions the clinical significance of occult nodal metastasis in PTMC. One limitation of
the study is that the mean follow-up time was only approximately 4 years, which perhaps
does not allow enough time for subclinical metastasis to become overt.
When PTC is larger than 1 cm, the risk of nodal metastases is higher.9 Although
there is arguably no effect on survival with nodal metastasis, there is the concern of an
increased risk of recurrence. As was the case in the central compartment, some authors
use the presence of the lymph nodes alone as an argument for a comprehensive approach
to the lateral neck.10, 15 The recommendations are made with the goal of reducing
recurrence, but these studies have not yet completed the follow-up to prove that an
aggressive approach with ipsilateral modified radical neck dissection (MRND) actually
results in lower recurrences. No prospective, randomized trials exist to identify the best
management of the lateral neck in thyroid cancer because of the limitations discussed
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earlier.50 And, unfortunately, the largest retrospective studies examining prognostic
factors in DTC do not provide adequate detail to draw conclusions about the management
of the neck.3, 4, 6, 20, 24
The NCDB report of 53,856 case of thyroid cancer treated in the US between 1985
and 1995 was able to observe that the majority of patients with DTC did not undergo
lymph node dissection and that lymph node sampling was more popular than formal,
comprehensive lymph node dissection.3 For PTC, for example, 14.6% of all patients
underwent a limited lymph node dissection as part of their treatment, whereas 7.2% of
patients had a radical or modified radical neck dissection. Another observation was that
38.3% of patients with PTC within this population received radiotherapy (usually RAI)
after surgery. The reported 10-year overall relative survival for PTC in this study was
93%. However, without a means of identifying the indications for the above treatments
and analysis of who received which combinations of surgery and radioactive iodine, there
is no way to make meaningful conclusions on how the treatments affected outcomes. The
Surveillance, Epidemiology and End Results (SEER) program is another large database
(15,698 patients) that is similarly limited by lack of treatment based analysis and controls.4
When lateral lymph node metastases are clinically apparent, the need for surgical
excision is more obvious. In the past, lateral lymph nodes have been simply excised via
“node picking” procedures, but these procedures are seldom advocated today. The current
recommendation of the ATA guidelines5 is for functional compartmental en-bloc
dissection for clinically positive nodes. Although this approach seems to be more
oncologically sound, there are limited data to prove that it truly improves outcomes. In
fact, in a group of 859 patients treated for PTC at the Mayo Clinic between 1946 and 1970
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when “node picking” was the more popular approach for cervical nodes and postoperative
iodine was only used in 3% of patients, the nodal recurrence rate was only 6%.20 The
overall mortality observed at 30 years was only 3% above that expected, with 6.5% of the
patients dying from PTC. Unfortunately, this study failed to compare the effect of node
picking (245/400) versus MRND (125/400) in regards to recurrence or mortality in their
patients with cervical node excisions.
On the other hand, while only 6.5% of patients dying from the disease may look
good in comparison to other types of cancer, a more aggressive approach that does not
significantly increase morbidity would be warranted to further minimize mortality in this
typically curable disease. In two studies looking at small groups of patients with DTC,
Kupferman et al14, 51 indicated that the pattern of lymph node metastases in patients with
clinically positive necks warranted a comprehensive neck dissection with inclusion of
levels II through V and that this procedure can be performed with acceptable morbidity.
In 2004, Wang at el52 reported a series of patients with DTC who were managed
using the above suggested approach: LND only for clinically palpable nodes, and MRND
with preservation of the submandibular triangle when these nodes were excised. Of the
508 patients, 44 required a neck dissection for clinically palpable lateral nodes. Only 3%
of the 464 patients who did not undergo initial neck dissection recurred in the lateral
cervical nodes. They discovered that recurrence was more likely when the initial tumor is
larger than 4 cm. Of the 16 patients who recurred in the lateral neck, 5 were younger than
45 years and were alive and free of disease. Of the 11 who recurred and were over 45
years, however, 4 had died of their thyroid cancer. This led them to conclude that
aggressive attempts to detect and treat occult lateral cervical nodes was for the most part
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unnecessary, but could be considered in older patients with large primary tumors.
Lebouleux et al23 examined 148 patients with lymph node metastases (140 patients) or
extrathyroidal extension (8 patients) who underwent total thyroidectomy with central and
ipsilateral en bloc neck dissection of levels III and IV followed by RAI. The neck
dissection was extended to include levels II and V if frozen section of the levels III and IV
showed metastatic involvement. Of these high-risk patients, 22% had persistent disease on
the post-ablation WBS. This allowed them to identify significant risk factors for
persistent disease, which include > 10 lymph node metastases, lymph nodes with
extracapsular extension, and tumor size > 4 cm. Still, the ten-year disease specific
survival was 99%, and the recurrence rate for the patients with a normal post-ablation
WBS was 7% with an 8 year mean follow up.
The ATA guidelines agree with the findings and recommendations of these two studies.5
They suggest that a compartmental lymph node dissection should be performed for
patients with biopsy-proven metastatic cervical lymphadenopathy, especially when they
are likely to fail radioactive iodine.
Dissection of the lateral compartment can be accomplished through a single
transverse incision by extending the thyroidectomy incision laterally to the anterior border
of the trapezius. A second transverse incision (MacFee incision) may be added superiorly,
when necessary, to facilitate exposure of the upper neck nodes. Alternatively, a modified
apron incision that incorporates the thyroidectomy incision can be used.
2006 ATA Guidelines: Lateral neck compartmental lymph node dissection should be
performed for patients with biopsy-proven metastatic cervical lymphadenopathy detected
clinically or by imaging, especially when they are likely to fail radioactive iodine
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treatment based on lymph node size, number, or other factors, such as aggressive
histology of the primary tumor.

Sentinel Node Biopsy
Sentinel lymph node (SLN) biopsy is a technique that has gained wide acceptance
in the management of breast cancer and melanoma. Recently, it has been offered as an
option in the management of DTC. Fukui et al53 performed SLN biopsy in 22 patients by
injecting methylene blue around the primary tumor site at the time of surgery. They
proceeded to perform MRND in all of the patients. They reported a 90.5% concordance
rate between the SLN findings and the regional lymph node status. Dzodic54 offered the
SLN biopsy as means to determine which patients with clinically negative necks could
benefit from MRND. He performed the procedure in 40 patients with DTC and had a
92.5% SLN identification rate. Although the procedure can be done, it is unclear if it
would be beneficial in DTC. Breast cancer and melanoma differ from DTC in that lymph
node metastasis has a definite and important impact on prognosis for these tumor types.
Additionally, regional lymphadenectomy for these cancers is associated with significant
morbidity. Currently, neck dissection is only recommended for clinically or ultrasound
apparent nodal metastases in patients with DTC.5 Because the impact of occult lymph
node metastasis on survival in DTC has been shown to be low and possibly insignificant,
it is unclear whether SLN biopsy would alter outcomes. The influence of occult lymph
node metastasis on recurrence is likely higher, however, and if occult cervical metastases
could in any way account for the small percentage of patients who die of DTC, then their
identification would be beneficial. The ATA guidelines5 suggest that future research must
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be aimed at developing techniques to identify small cervical metastases in DTC for these
reasons. SLN biopsy has potential to fulfill that goal. A large study demonstrating not
only its feasibility and accuracy, but more importantly its benefit, must be performed
before SLN is adopted in the workup of DTC.

Minimally invasive/endoscopic neck dissection
SLN biopsy was developed as a method to minimize morbidity by preventing
unnecessary en bloc lymph node dissections. Minimally invasive and endoscopic
techniques are proposed as methods to minimize morbidity when lymph node dissections
are necessary. Additionally, a minimally invasive approach to thyroidectomy is gaining in
popularity, which will likely lead to increased patient awareness and demand for the
technique within this patient population. Terris et al55 demonstrated the feasibility of an
endoscopic selective neck dissection using a porcine model. Lombardi et al56 recently
described a minimally invasive technique using video assistance for performing a lateral
neck dissection, which they employed in 2 patients with PTC. Additionally, the
combination of SLN biopsy with an endoscopic approach has been offered as an initial
low-morbidity staging procedure.57 This would allow for an easy conversion to an
endoscopic neck dissection if the sentinel node proves to be positive. As with SLN
biopsy, however, the role of this technique in DTC is limited due to the apparent lack of
significance of occult lymph node metastasis. Therefore, minimally invasive techniques
must be proven to be safe and effective for N+ necks, or prophylactic dissection of the
lateral neck in DTC must be proven to be beneficial before endoscopic-assisted neck
dissection can be considered useful in the management of DTC. Indeed, if occult
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metastases are proven to affect prognosis, then SLN biopsy and minimally invasive
techniques could play an important role in the future management of the neck in DTC.

Conclusions
DTC is a relatively rare malignancy carrying a favorable prognosis. Survival rates
exceed 90%, but patients often survive with evidence of distant disease and die of
unrelated causes, pointing to a relatively indolent but potentially lethal process. Despite a
high long-term survival rate, recurrences are common and death from DTC does occur,
even if in less than 10% of patients. An appropriately aggressive treatment of DTC must
limit the risk of recurrence and death while minimizing treatment morbidity and
recognizing the indolent course that DTC follows in most patients. This is especially true
of the management of the neck, where lymph node metastases occur frequently and are
associated with an unclear effect on prognosis. The 2006 updated treatment guidelines by
the ATA are based on the currently available data, and make an effort to reach that
treatment balance. An aggressive compartment oriented neck dissection is recommended
for patients with evidence of cervical lymph node metastasis on physical exam or
ultrasonograpy, but elective dissection of the negative lateral neck is not.
The ATA guidelines are based largely on retrospective reviews because the
infrequency of the disease combined with its high survival rate limits the practicality of a
large randomized prospective trial. Although a randomized prospective trial would
provide the best evidence for management protocols, the ATA guidelines are a valuable
interpretation of the current evidence, which at times is conflicting. A uniform approach
to the management of DTC should limit the chance of undertreatment and should improve
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the ability to analyze outcomes in the future. Both would aid in further lowering the risk
of recurrence and death from thyroid cancer.
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